Abstract
Plain Language Summary: Financial toxicity is increasingly being recognized as an important and devastating consequence of cancer treatment that receives little attention when clinical trials are being designed. There is a significant need to obtain this important information in an era of increasingly expensive anticancer treatments. Patients who are informed of all implications of therapy—efficacy, side effects, cost, and broader financial impact—are able to select the best cancer treatment for themselves.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1143-1148 |
| Number of pages | 6 |
| Journal | cancer |
| Volume | 129 |
| Issue number | 8 |
| DOIs |
|
| State | Published - Apr 15 2023 |
Funding
Reshma Jagsi has received stock options as compensation for her advisory board role in Equity Quotient, a company that evaluates culture in health care companies. She has received personal fees from the National Institutes of Health as a special government employee (in her role as a member of the Advisory Committee on Research on Women’s Health and the Board of Scientific Counselors), the Greenwall Foundation, and the Doris Duke Charitable Foundation. She has received grants for unrelated work from the National Institutes of Health, the Doris Duke Charitable Foundation, the Greenwall Foundation, the American Cancer Society, the Susan G. Komen Foundation, and Blue Cross Blue Shield of Michigan for the Michigan Radiation Oncology Quality Consortium. She has a contract to conduct an investigator‐initiated study with Genentech. She has served as an expert witness for Sherinian and Hasso, Dressman Benzinger LaVelle, and Kleinbard LLC. She is an uncompensated member of the National Academies of Sciences, Engineering, and Medicine’s Committee on Women in Science, Engineering, and Medicine. Laila A. Gharzai declares no conflicts of interest. Reshma Jagsi’s effort was supported by a Senior Scholar Grant from the Susan G. Komen Foundation.
ASJC Scopus subject areas
- Oncology
- Cancer Research
